Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
17.99
-0.18 (-0.99%)
At close: Apr 13, 2026, 4:00 PM EDT
17.99
0.00 (0.00%)
After-hours: Apr 13, 2026, 4:10 PM EDT
Crescent Biopharma Revenue
Crescent Biopharma had revenue of $10.84M in the quarter ending December 31, 2025.
Revenue (ttm)
$10.84M
Revenue Growth
n/a
P/S Ratio
55.10
Revenue / Employee
$246,455
Employees
44
Market Cap
597.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00K | -65.00K | -86.67% |
| Dec 31, 2022 | 75.00K | -1.08M | -93.53% |
| Dec 31, 2021 | 1.16M | -9.00M | -88.59% |
| Dec 31, 2020 | 10.16M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 18.50M | -1.57M | -7.83% |
| Dec 31, 2015 | 20.07M | 5.04M | 33.56% |
| Dec 31, 2014 | 15.03M | 11.03M | 276.37% |
| Dec 31, 2013 | 3.99M | -11.26M | -73.83% |
| Dec 31, 2012 | 15.26M | 11.44M | 300.05% |
| Dec 31, 2011 | 3.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 418.63M |
| CorMedix | 311.71M |
| Prothena Corporation | 9.68M |
| Aclaris Therapeutics | 7.83M |
| Prime Medicine | 4.63M |
| Ocugen | 4.41M |
| Upstream Bio | 2.85M |
| ProKidney | 893.00K |
CBIO News
- 17 days ago - Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewsWire
- 6 weeks ago - Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 weeks ago - Crescent Biopharma to Present at March Investor Conferences - GlobeNewsWire
- 7 weeks ago - Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors - GlobeNewsWire
- 2 months ago - Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors - GlobeNewsWire
- 4 months ago - Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors - GlobeNewsWire
- 4 months ago - Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics - GlobeNewsWire